checkAd
    Startseite > Aktien > Olema Pharmaceuticals > Nachrichten
    Olema Pharmaceuticals Aktie
    9,6800
     
    USD
    +0,62 %
    +0,0600 USD
    Letzter Kurs 31.05.24 Nasdaq
    9,6800
     
    USD
    2.700 STK
    Geldkurs 31.05.24
    9,6900
     
    USD
    8.200 STK
    Briefkurs 31.05.24
    ISIN: US68062P1066 · WKN: A2QGWT · SYM: OLMA · USA

    Neueste Nachrichten

    Olema Oncology to Participate in Upcoming Investor Conferences in June
    28.05.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
    15.05.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
    08.05.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
    08.05.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    02.05.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology to Participate in Upcoming Investor Conferences in May
    01.05.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
    08.04.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    02.04.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
    11.03.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
    06.03.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.03.24 · globenewswire · Olema Pharmaceuticals
    Olema Oncology to Participate in Upcoming Investor Conferences
    06.02.24 · globenewswire · Olema Pharmaceuticals